Grayscale Bitcoin Mini Trust ETF

Bitcoin Is Down 3% in October and Ethereum 12%. Which Should a First-Time Buyer Pick?

247 Wallst•2h ago

Monero (XMR) and Zcash (ZEC) Beat Bitcoin This Week. Can the Privacy Coins Keep It Up?

247 Wallst•3h ago

XRP Held Flat This Week While Bitcoin, Ethereum and Solana Fell. Is It Breaking Away From Bitcoin?

247 Wallst•4h ago

Bitcoin Analysis: BTC Slipped Below $80,000 Again. Is $77,600 the Next Stop?

247 Wallst•4h ago

Strategy Booked an $8.3 Billion Bitcoin Loss Last Quarter. Could Q3 Show a Gain?

24/7 Wall Street•4h ago

David Schwartz Says XRP Should Gain if the XRP Ledger Succeeds. Is He Right?

247 Wallst•5h ago

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

GuruFocus•5h ago

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

GuruFocus•5h ago

Which Cryptos Could Outperform Bitcoin Before the End of 2026?

247 Wallst•21h ago

Is Solana a Good Investment After a 65% Drop From Its Record High?

247 Wallst•22h ago

Bitcoin or Gold: Which Is the Better Inflation Hedge With Prices Up 3.7%?

247 Wallst•23h ago

Can Bitcoin Get Back Above $85,000 in November?

247 Wallst•23h ago

XRP Price Prediction: Where Could XRP Be by the End of November?

247 Wallst•1d ago

Ripple’s XRP Is 65% Below Its Record High. Where Could It Be in 10 Years?

247 Wallst•1d ago

How Low Could Avalanche (AVAX) Go After an 11% Drop in a Week?

247 Wallst•1d ago

Is Bitcoin Dead? CZ Says Those Calls Have Marked the Best Times to Buy

247 Wallst•1d ago

Bitcoin ETFs Just Had Their Biggest Outflow Day Since June. Is the Selling Over?

24/7 Wall Street•1d ago

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

GuruFocus•1d ago

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

GuruFocus•1d ago

XRP Analysis: XRP Shorts on Bitfinex Have Doubled in Two Weeks. Could a Squeeze Follow?

247 Wallst•1d ago